PatentMay 19, 2026, 08:32 AM
Autonomix Medical Secures New US Patent for Transvascular Technology
AI Summary
Autonomix Medical, Inc. announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,544,131. This new patent, titled "Systems, Methods, and Devices for Monitoring and Treatment of Tissues Within And/Or Through a Lumen Wall," significantly strengthens the company's global intellectual property portfolio. The patent covers catheter-based transvascular tools that enable real-time nerve activity sensing through vessel walls and objective assessment of treatment effectiveness, supporting a closed-loop, data-driven approach to nerve-targeted procedures.
Key Highlights
- U.S. Patent No. 12,544,131 issued by USPTO.
- Patent titled "Systems, Methods, and Devices for Monitoring and Treatment of Tissues Within And/Or Through a Lumen Wall."
- Strengthens intellectual property for transvascular and neuromodulation platform technologies.
- Covers ability to sense nerve activity through vessel walls and assess treatment in real-time.
- Includes claims for multi-site electrophysiological sensing and closed-loop control capabilities.
- Supports adaptive neuromodulation and data-driven nerve-targeted procedures.
- Applicable across a broad range of electrophysiological signal types and therapeutic modalities.
- Existing IP portfolio has expirations extending into the late 2030s.
Price Impact
More from AMIX